Skip to content

REVIVE-PEEP

The REVIVE-PEEP Trial: positive end-expiratory pressure versus sham valve/zero end-expiratory pressure in cardiopulmonary resuscitation during manual ventilation to improve neurological outcomes at discharge in adult patients suffering an out-of-hospital cardiac arrest - an investigator-initiated, pragmatic, registry-based, multicenter, parallel-group, triple-blind randomized controlled superiority clinical trial in the ARREST registry’ - REVIVE-PEEP

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON61400
Enrollment
3200
Registered
2025-02-07
Start date
2026-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac arrest Cardiac arrest

Interventions

Participating ambulance services will use pre-assembled CPR kits, containing a bag-valve-mask system with either a PEEP valve or a sham valve. These kits will be 1:1 randomized, with the PEEP valve de

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult patients with out-of-hospital cardiac arrest who receive an advanced airway

Exclusion criteria

Exclusion criteria: Any potential subject who meets the following criteria will be excluded from the study:Suspected traumatic cardiac arrestSuspected cardiac arrest after drowningAirway management and ventilation initiated with a non-study resuscitator by a provider from a non-participating ambulance serviceContinuous use of mechanical ventilationTraumatic OHCA (e.g. due to blunt or penetrating trauma) and cardiac arrest following drowning will be excluded due to their distinct pathophysiology. In contrast, arrests resulting from hanging, strangulation, or foreign body airway obstruction will be included. The trial will not exclude females of childbearing age or those with known or suspected pregnancy. Short-term mechanical ventilation used to facilitate patient transport (e.g., during fire department hoisting) will be allowed, provided it is not initiated directly after airway management and used only during transport, without being continued beyond the immediate transport period. 

Design outcomes

Primary

MeasureTime frame
The primary endpoint is neurological outcome at hospital discharge, assessed by the utility-weighted modified Rankin Scale within the principal stratum estimand. 

Secondary

MeasureTime frame
The secondary objectives are of an exploratory nature and should be interpreted as preliminary findings. They aim to generate hypotheses for future studies rather than provide definitive conclusions.Safety parametersTo evaluate the effect of the intervention on the occurrence of clinically significant pneumothorax, defined as the need for drainage through (needle) thoracostomy or chest tube.To evaluate the effect of the intervention on successful ventricular fibrillation termination, defined as the presence of a non-shockable rhythm 5 seconds after the shock.  Physiological parametersTo evaluate the effect of the intervention on airway opening index, a measure of intra-arrest intrathoracic airway closure.To evaluate whether the intervention affects thoracic impedance, reflecting changes in lung inflation during CPR.To evaluate the effect of the intervention on the intra-arrest blood gas parameters (pO2, pCO2, pH, base excess, bicarbonate, lactate) drawn in the hospital.To evaluate the effect of the intervention on atelectasis, defined as the fractional area of atelectasis on standardized CT scan if made as part of routine post-resuscitation care.  Clinical outcomesTo evaluate the effect of the intervention on 30-day survival.To evaluate the effect of the intervention on dichotomized neurological favorable survival, as indicated by a score of 3 or less on the mRS.To evaluate the effect of the intervention on health-related quality of life among survivors at 6 months after cardiac arrest, measured through the EQ-5D-5L questionnaire.

Countries

Netherlands

Contacts

Public ContactJ.A. Eijk

Amsterdam UMC

arrest@amsterdamumc.nl+31205669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 10, 2026